> Details

Globig, Anna-Maria; Strohmeier, Valentina; Surabattula, Rambabu; Leeming, Diana J.; Karsdal, Morten A.; Heeg, Maximilian; Kindle, Gerhard; Goldacker, Sigune; von Spee-Mayer, Caroline; Proietti, Michele; Bausch, Birke; Bettinger, Dominik; Schultheiß, Michael; Thimme, Robert; Schuppan, Detlef; Warnatz, Klaus

Evaluation of Laboratory and Sonographic Parameters for Detection of Portal Hypertension in Patients with Common Variable Immunodeficiency

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Evaluation of Laboratory and Sonographic Parameters for Detection of Portal Hypertension in Patients with Common Variable Immunodeficiency
  • Contributor: Globig, Anna-Maria; Strohmeier, Valentina; Surabattula, Rambabu; Leeming, Diana J.; Karsdal, Morten A.; Heeg, Maximilian; Kindle, Gerhard; Goldacker, Sigune; von Spee-Mayer, Caroline; Proietti, Michele; Bausch, Birke; Bettinger, Dominik; Schultheiß, Michael; Thimme, Robert; Schuppan, Detlef; Warnatz, Klaus
  • imprint: Springer Science and Business Media LLC, 2022
  • Published in: Journal of Clinical Immunology
  • Language: English
  • DOI: 10.1007/s10875-022-01319-0
  • ISSN: 0271-9142; 1573-2592
  • Keywords: Immunology ; Immunology and Allergy
  • Origination:
  • Footnote:
  • Description: <jats:title> Abstract</jats:title><jats:p>Timely detection of portal hypertension as a manifestation in a subgroup of patients with common variable immunodeficiency (CVID) represents a challenge since it is usually not associated with liver cirrhosis. To identify relevant markers for portal hypertension, we evaluated clinical history, laboratory parameters, and abdominal ultrasound including liver elastography and biomarkers of extracellular matrix formation. Twenty seven (6%) of 479 CVID patients presented with clinically significant portal hypertension as defined by either the presence of esophageal varices or ascites. This manifestation occurred late during the course of the disease (11.8 years after first diagnosis of CVID) and was typically part of a multiorgan disease and associated with a high mortality (11/27 patients died during follow up). The strongest association with portal hypertension was found for splenomegaly with a longitudinal diameter of &gt; 16 cm. Similarly, most patients presented with a liver stiffness measurement (LSM) of above 6.5 kPa, and a LSM above 20 kPa was always indicative of manifest portal hypertension. Additionally, many laboratory parameters including Pro-C4 were significantly altered in patients with portal hypertension without clearly increasing the discriminatory power to detect non-cirrhotic portal hypertension in CVID. Our data suggest that a spleen size above 16 cm and an elevated liver stiffness above 6.5 kPa should prompt further evaluation of portal hypertension and its sequelae, but earlier and better liquid biomarkers of this serious secondary complication in CVID are needed.</jats:p>